Real-World check: new drug for rare skin condition shows promise in small study
NCT ID NCT05670821
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 21 times
Summary
This study looked at 52 patients in Japan with generalized pustular psoriasis (GPP), a rare and severe skin disease, who received a new treatment called spesolimab. Researchers monitored side effects and how the disease behaved in real-world clinics, not just in controlled trials. The goal was to better understand the drug's safety and effectiveness outside of a research setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, 1416017, Japan
Conditions
Explore the condition pages connected to this study.